Prevalence and association of statin with mortality risk among older US cancer survivors with and without coronary heart disease

Clicks: 1
ID: 323362
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #198 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Cancer survivors exhibit high cardiovascular disease prevalence. Statins' pleiotropic effects may improve outcomes, but evidence in those with coronary heart disease remains limited. Purpose To investigate statin use prevalence and its association with cause-specific mortality in older U.S. cancer survivors, stratified by coronary heart disease (CHD) status. Methods This retrospective cohort study utilized data from four NHANES cycles linked to 2019 mortality files. Statin exposure was identified via prescription medication data. Mortality risks were assessed using Cox proportional hazards models, with survival rates illustrated by Kaplan-Meier curves. Subgroup analyses explored potential effect modifiers. Results Among 2,714 cancer survivors (mean age 75.5 years; 54.3% men), 23.9% had CHD (Table 1). Statin prevalence tripled from 20.0% to 56.0%, showing distinct trends by CHD and sex (Figure 1). Over a mean 81-month follow-up, CHD patients using statins had significantly lower all-cause (52.0% vs. 72.8%), cardiac (18.3% vs. 25.9%), and cancer-related mortality (11.5% vs. 18.0%) than non-users (all P<0.05) (Table 2). The Kaplan-Meier curves showed that the statin use demonstrated better survival outcomes across all categories of mortality (all log-rank p < 0.05) (Figure 2). In fully adjusted models, statin use in CHD patients was independently associated with reduced all-cause (HR 0.80), cardiac (HR 0.77), and cancer-related mortality (HR 0.77) (Table 3). No such reduction in cancer mortality was observed in non-CHD individuals (Table 4). Conclusion Statin use is associated with significantly reduced cause-specific mortality in older cancer survivors with CHD, but not in those without CHD. Personalizing statin therapy based on CHD status may optimize survival outcomes.Abstract Picture 1 Abstract Picture 2
Reference Key
openalex_W7172268991 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors J Alifu, C Wenliang
Journal European heart journal supplements : journal of the European Society of Cardiology
Year 2026
DOI
10.1093/eurheartjsupp/suag097.129
URL
https://doi.org/10.1093/eurheartjsupp/suag097.129
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.